👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

JD.com Shares Soar after Beating Sales Estimates, Acotec Tumbles in HKSE Debut

Published 24/08/2021, 03:02 pm
© Reuters.
JD
-
9618
-
6669
-

By Gina Lee

Investing.com – JD.com Inc. shares soared more than 10% on Tuesday after the company exceeded sales estimates thanks to improving consumer spending and seemingly undeterred by tightening regulations on the Chinese internet sector.

JD.com shares in Hong Kong (HK:9618) soared 10.10% to HK$268.20 ($41.32) by 12:51 AM ET (4:51 AM GMT). The company’s New York shares (NASDAQ:JD) rose 3.32% to $65.73.

The company recorded a 26% rise in revenue to CNY253.8 billion ($39.1 billion) for the three months ended June 2021. Higher transaction volumes during the annual JD.com 6.18 shopping festival and the double-digit rebound in retail spending in China during the June quarter, also contributed to the better-than-expected results.

However, the latest outbreak of COVID-19 in China slowed down the country’s economic recovery, as much of the country went under strict lockdown towards the end of July.

Although JD.com hasn’t faced a high-profile probe or crackdown since regulations were tightened, its shares have dropped around 40% from a high hit in February as investors retreat from the sector.

“JD has always paid great importance to data security and personal information, so the arrival of the new regulations is not making a big impact on us in terms of our advertising business,” Chief Executive Officer Xu Lei said during a conference call.

However, “we are faced with multiple challenges,” he added.

Meanwhile, medical device maker Acotec Scientific Holdings Ltd. (HK:6669) made a dismal debut on the Hong Kong Stock Exchange (HKSE) on Tuesday. Its shares tumbled 25.13% to HK%17.82, after opening at HK$18.32.

Healthcare technology platforms also face tightened regulations, with Chinese media reporting during the previous week that approval from the government for the methods of diagnoses, prescriptions and use of medicine is now required to ensure safety.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.